Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma

Cancer Gene Therapy volume 12, pages 122–132 (2005)Cite this article

Abstract

Our previous study showed that J558 myeloma cells engineered CD40L lost their tumorigenicity in syngeneic mice, and the inoculation of J558/CD40L tumor cells further led to the protective immunity against wild tumors. In the present study, we investigated whether the vaccine can exert more efficient antitumor immunity by combination with adenovirus mediated CD40L gene therapy and immature dendritic cells (iDCs). The results demonstrated that intratumoral administration of iDCs 2 days after AdVCD40L injection, not only significantly suppressed the tumor growth, but also eradiated the established tumors in 40% of the mice. The potent antitumor effect produced by the combination therapy correlated with high expression of MHC, costimulatory and Fas molecules on J558 cells, which was derived from CD40L transgene expression. In addition, transgene CD40L expression could dramatically induce J558 cell apoptosis. Effectively capturing apoptotic bodies by iDCs in vivo could induce DC maturation, prime tumor-specific CTLs and tend to Th1-type immune response. Finally, in vivo depletion experimentation suggested both CD4+ and CD8+ T cells were involved in mediating the antitumor immune responses of combined treatment of AdVCD40L and iDCs, with CD8+ T cells being the major effector. These findings could be beneficial for designing strategies of DCs vaccine and CD40L for anticancer immunotherapy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

References

  1. Steinman RM, Bancherear J . Dendritic cells and the control of immunity. Nature. 1998;392:245–252.

    Article  Google Scholar 

  2. Cella M, Sallusto F, Lanzavecchia A . Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol. 1997;9:10–16.

    Article  CAS  Google Scholar 

  3. Nestle F, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328–332.

    Article  CAS  Google Scholar 

  4. Nair S, Snyder D, Rouse B, et al. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer. 1997;70:706–715.

    Article  CAS  Google Scholar 

  5. Bancherau J, Steinman RM . Dendritic cells and the control of immunity. Nature. 1998;392:245–252.

    Article  Google Scholar 

  6. Hart DN . Dendritic cells: unique leukocytes populations which control the primary immune response. Blood. 1997;90:3245–3287.

    CAS  Google Scholar 

  7. Shreedhar V, Moodycliffe AM, Ullrich SE, et al. Dendritic cells require T cells for functional maturation in vivo. Immunity. 1999;11:625–636.

    Article  CAS  Google Scholar 

  8. Schoenberger SP, Toes RE, van der Voort EI, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480.

    Article  CAS  Google Scholar 

  9. Hermans IF, Ritchie DS, Daish A, et al. Impaired ability of MHC class II−/− dendritic cells to provide tumor protection is rescued by CD40 ligation. J Immunol. 1999;163:77–81.

    CAS  PubMed  Google Scholar 

  10. Moodycliffe AM, Shreedhar V, Ullrich SE, et al. CD40–CD40 ligand interactions in vivo regulate migration of antigen-bearing dendritic cells from the skin to draining lymph nodes. J Exp Med. 2000;191:2011–2020.

    Article  CAS  Google Scholar 

  11. Kurts C, Heath WR, Carbone FR, et al. Constitutive class I-restricted exogenous presentation of self antigens in vivo. J Exp Med. 1996;184:923.

    Article  CAS  Google Scholar 

  12. Larsson M, Messmer D, Somersan S, et al. Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8+ T cells. J Immunol. 2000;165:1182–1190.

    Article  CAS  Google Scholar 

  13. Schuurhuis DH, Laban S, Toes RE, et al. Immature dendritic cells acquire CD8+ cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. J Exp Med. 2000;192:145–150.

    Article  CAS  Google Scholar 

  14. Kelleher M, Beverley PC . Lipopolysaccharide modulation of dendritic cells is insufficient to mature dendritic cells to generate CTLs from naive polyclonal CD8+ T cells in vitro, whereas CD40 ligation is essential. J Immunol. 2001;167:6247–6255.

    Article  CAS  Google Scholar 

  15. Watanabe S, Kagamu H, Yoshizawa H, et al. The duration of signaling through CD40 directs biological ability of dendritic cells to induce antitumor immunity. J Immunol. 2003;171:5828–5836.

    Article  CAS  Google Scholar 

  16. Miyashita T, McIlraith MJ, Grammer AC, et al. Bidirectional regulation of human B cell responses by CD40–CD40 ligand interactions. J Immunol. 1997;158:4620–4633.

    CAS  PubMed  Google Scholar 

  17. Young LS, Eliopoulos AG, Gallagher NJ, et al. CD40 and epithelial cells: across the great divide. Immunol Today. 1998;19:502–506.

    Article  CAS  Google Scholar 

  18. Pellat-Deceunynck C, Bataille R, Robillard N, et al. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells. Blood. 1994;84:2597–2603.

    CAS  PubMed  Google Scholar 

  19. Tong AW, Seamour B, Chen J, et al. CD40 ligand-induced apoptosis is Fas-independent in human multiple myeloma cells. Leukemia Lymphoma. 2000;36:543–558.

    Article  CAS  Google Scholar 

  20. Teoh G, Ai YT, Urashima M, et al. CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. Blood. 2000;95:1039–1046.

    CAS  PubMed  Google Scholar 

  21. Bergamo A, Bataille R, Pellat-Deceunynck C . CD40 and CD95 induce programmed cell death in the human myeloma cell line XG2. Br J Haematol. 1997;97:652–655.

    Article  CAS  Google Scholar 

  22. Liu Y, Qureshi M, Xiang J . Antitumor immune responses derived from transgenic expression of CD40 ligand in myeloma cells. Cancer Biother Radiopharm. 2002;17:11–18.

    Article  Google Scholar 

  23. Wright P, Braun R, Babiuk L, et al. Adenovirus-mediated TNF-α gene transfer induces significant tumor regression in mice. Cancer Biother Radiopharm. 1999;14:49–57.

    Article  CAS  Google Scholar 

  24. Xiang J, Moyana T . Regression of engineered tumor cells secreting cytokines is related to a shift in host cytokine profile from type 2 to type 1. J Interferon Cytokine Res. 2000;20:349–354.

    Article  CAS  Google Scholar 

  25. Song W, Kong H, Carpenter H, et al. Dendritic cells genetically modified with adenovirus vector encoding the cDNA for a model antigen induce protective and therapeutic antitumor immunity. J Exp Med. 1997;186:1247–1256.

    Article  CAS  Google Scholar 

  26. Dotti G, Savoldo B, Takahashi S, et al. Adenovector-induced expression of human-CD40-ligand (hCD40L) by multiple myeloma cells: a model for immunotherapy. Exp Hematol. 2001;29:952–961.

    Article  CAS  Google Scholar 

  27. Albert ML, Pearce SFA, Francisco LM, et al. Immature dendritic cells phagocytose apoptotic cells via βαvβ5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med. 1998;188:1359–1368.

    Article  CAS  Google Scholar 

  28. Grossmann M, Brown M, Bresnner M . Antitumor responses induced by transgenic expression of CD40 ligand. Hum Gene Ther. 1997;8:1935–1943.

    Article  CAS  Google Scholar 

  29. Tong AW, Stone MJ . Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther. 2003;10:1–13.

    Article  CAS  Google Scholar 

  30. Van Kooten C, Bancherau J . Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol. 1997;9:330–337.

    Article  CAS  Google Scholar 

  31. Schultze JL, Michalak S, Seamon MJ, et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Investig. 1997;100:2757–2765.

    Article  CAS  Google Scholar 

  32. Schultze JL, Seamon MJ, Michalak S, et al. Autologous tumor infiltrating T cells cytotoxic for follicular lymphoma cells can be expanded in vitro. Blood. 1997;89:3806–3816.

    CAS  Google Scholar 

  33. Cantwell MJ, Wierda WG, Lossos IS, et al. T cell activation following infection of primary follicle center lymphoma B cells with adenovirus encoding CD154. Leukemia. 2001;15:1451–1457.

    Article  CAS  Google Scholar 

  34. Albert ML, Sauter B, Bhardwaj N . Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature. 1998;392:86–89.

    Article  CAS  Google Scholar 

  35. Hoffmann TK, Meidenbauer N, Whiteside DG . Generation of tumor-specific T lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res.. 2000;60:3542–3549.

    CAS  PubMed  Google Scholar 

  36. Sotomayor EM, Borrello I, Tubb E, et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med. 1999;5:780–787.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by a Research Grant (ROP-15151) of the Canadian Institute of Health Research. Yongqing Liu is supported by a Fellowship Award of the Leukemia Research Fund of Canada.

Author information

Authors and Affiliations

  1. Research Unit, Saskatchewan Cancer Agency and Departments of Microbiology, Immunology and Oncology, College of Medicine, University of Saskatchewan, Saskatoon, Saskatchewan, Canada, S7N 0W0

    Yongqing Liu, Dajing Xia, Fang Li & Jim Xiang

  2. Gene Therapy Branch, National Institute of Dental Research, National Institute of Health, Bethesda, Maryland, 20892, USA

    Changyu Zheng

Authors
  1. Yongqing Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dajing Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fang Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Changyu Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jim Xiang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jim Xiang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, Y., Xia, D., Li, F. et al. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma. Cancer Gene Ther 12, 122–132 (2005). https://doi.org/10.1038/sj.cgt.7700757

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700757

Keywords

This article is cited by

Search

Advanced search

Quick links